دورية أكاديمية
أعرض في EDS

Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC.

التفاصيل البيبلوغرافية
العنوان: Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC.
المؤلفون: Das A; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Shapiro DD; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Craig JK; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Abel EJ; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. abel@urology.wisc.edu.
المصدر: Nature reviews. Urology [Nat Rev Urol] 2023 Nov; Vol. 20 (11), pp. 654-668. Date of Electronic Publication: 2023 Jul 03.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500082 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-4820 (Electronic) Linking ISSN: 17594812 NLM ISO Abbreviation: Nat Rev Urol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Pub. Group
مواضيع طبية MeSH: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/surgery , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/surgery, Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Cytoreduction Surgical Procedures/methods ; Retrospective Studies ; Interferon-alpha/therapeutic use ; Nephrectomy/methods
مستخلص: Cytoreductive nephrectomy became accepted as standard of care for selected patients with metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients treated with cytoreductive nephrectomy in combination with interferon-α in two randomized clinical trials published in 2001. Over the past two decades, novel systemic therapies have shown higher treatment response rates and improved survival outcomes compared with interferon-α. During this rapid evolution of mRCC treatments, systemic therapies have been the primary focus of clinical trials. Results from multiple retrospective studies continue to suggest an overall survival benefit for selected patients treated with nephrectomy in combination with systemic mRCC treatments, with the notable exception of one debated clinical trial. The optimal timing for surgery is unknown, and proper patient selection remains crucial to improving surgical outcomes. As systemic therapies continue to evolve, clinicians have an increasing need to understand how to incorporate cytoreductive nephrectomy into the management of mRCC.
(© 2023. Springer Nature Limited.)
References: Flanigan, R. C. & Yonover, P. M. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin. Urol. Oncol. 19, 98–102 (2001). (PMID: 11354539)
Bosse, D. & Ong, M. Evolution in upfront treatment strategies for metastatic RCC. Nat. Rev. Urol. 17, 73–74 (2020). (PMID: 3191166910.1038/s41585-019-0271-6)
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022). (PMID: 3502020410.3322/caac.21708)
Flanigan, R. C. et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655–1659 (2001). (PMID: 1175964310.1056/NEJMoa003013)
Mickisch, G. H. et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966–970 (2001). (PMID: 1158375010.1016/S0140-6736(01)06103-7)
Bex, A. et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving Sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 5, 164–170 (2019). (PMID: 3054335010.1001/jamaoncol.2018.5543)
Mejean, A. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N. Engl. J. Med. 379, 417–427 (2018). (PMID: 2986093710.1056/NEJMoa1803675)
Larcher, A. et al. Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines. Eur. Urol. 78, 321–326 (2020). (PMID: 3250733510.1016/j.eururo.2020.05.014)
Noe, A. et al. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World J. Urol. 34, 1067–1072 (2016). (PMID: 2683235010.1007/s00345-016-1769-7)
Silagy, A. W. et al. Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer 127, 3946–3956 (2021). (PMID: 3428686510.1002/cncr.33790)
Psutka, S. P., Chang, S. L., Cahn, D., Uzzo, R. G. & McGregor, B. A. Reassessing the role of cytoreductive nephrectomy for metastatic renal cell carcinoma in 2019. Am. Soc. Clin. Oncol. Educ. Book. 39, 276–283 (2019). (PMID: 3109965710.1200/EDBK_237453)
Okada, S. L. et al. Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype. Cell Immunol. 323, 49–58 (2018). (PMID: 2910358710.1016/j.cellimm.2017.10.014)
Wu, Y., Yi, M., Niu, M., Mei, Q. & Wu, K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022). (PMID: 36163047951399210.1186/s12943-022-01657-y)
Monu, N. R. & Frey, A. B. Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol. Invest. 41, 595–613 (2012). (PMID: 23017137370188210.3109/08820139.2012.673191)
Lahn, M. et al. Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma. Eur. Urol. 35, 70–80 (1999). (PMID: 993379710.1159/000019821)
Zhao, Y., Niu, C. & Cui, J. Gamma-delta (γδ) T cells: friend or foe in cancer development? J. Transl. Med. 16, 3 (2018). (PMID: 29316940576118910.1186/s12967-017-1378-2)
Uzzo, R. G. et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res. 5, 1219–1229 (1999). (PMID: 10353760)
Li, L. et al. Skewed T-helper (Th)1/2- and Th17/T regulatory cell balances in patients with renal cell carcinoma. Mol. Med. Rep. 11, 947–953 (2015). (PMID: 2535215810.3892/mmr.2014.2778)
Anker, J., Miller, J., Taylor, N., Kyprianou, N. & Tsao, C. K. From bench to bedside: how the tumor microenvironment is impacting the future of immunotherapy for renal cell carcinoma. Cells https://doi.org/10.3390/cells10113231 (2021). (PMID: 10.3390/cells10113231348314528619121)
Prinz, P. U. et al. NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention. Int. J. Cancer 135, 1832–1841 (2014). (PMID: 2461539110.1002/ijc.28837)
Xia, Y. et al. Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway. Oncotarget 8, 37783–37795 (2017). (PMID: 28384121551494910.18632/oncotarget.16354)
Pantuck, A. J., Belldegrun, A. S. & Figlin, R. A. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin. Cancer Res. 13, 693s–696s (2007). (PMID: 1725529510.1158/1078-0432.CCR-06-1916)
Senbabaoglu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17, 231 (2016). (PMID: 27855702511473910.1186/s13059-016-1092-z)
Lucarelli, G. et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging 10, 3957–3985 (2018). (PMID: 30538212632665910.18632/aging.101685)
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F. & Opitz, C. A. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat. Rev. Drug Discov. 18, 379–401 (2019). (PMID: 3076088810.1038/s41573-019-0016-5)
Lucarelli, G. et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urol. Oncol. 35, 461 e415–461 e427 (2017). (PMID: 10.1016/j.urolonc.2017.02.011)
Li, H. et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat. Commun. 10, 4346 (2019). (PMID: 31554815676117810.1038/s41467-019-12361-9)
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594 e512 (2018). (PMID: 29656895593836510.1016/j.cell.2018.03.057)
Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell 173, 611–623.e617 (2018). (PMID: 29656891592763110.1016/j.cell.2018.02.020)
Figlin, R. A. Renal cell carcinoma: management of advanced disease. J. Urol. 161, 381–386 (1999). discussion 386-387. (PMID: 991540810.1016/S0022-5347(01)61897-4)
Dr Hall, B. & Abel, E. J. The evolving role of metastasectomy for patients with metastatic renal cell carcinoma. Urol. Clin. North Am. 47, 379–388 (2020). (PMID: 3260053910.1016/j.ucl.2020.04.012)
Kierney, P. C., van Heerden, J. A., Segura, J. W. & Weaver, A. L. Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann. Surg. Oncol. 1, 345–352 (1994). (PMID: 785053410.1007/BF02303572)
Tolia, B. M. & Whitmore, W. F. Jr. Solitary metastasis from renal cell carcinoma. J. Urol. 114, 836–838 (1975). (PMID: 119545810.1016/S0022-5347(17)67155-6)
Marcus, S. G. et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J. Urol. 150, 463–466 (1993). (PMID: 832657910.1016/S0022-5347(17)35514-3)
Wood, C. G. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol. Clin. North Am. 30, 581–588 (2003). (PMID: 1295375610.1016/S0094-0143(03)00026-0)
Janiszewska, A. D., Poletajew, S. & Wasiutynski, A. Spontaneous regression of renal cell carcinoma. Contemp. Oncol. 17, 123–127 (2013).
Milowsky, M. I. & Nanus, D. M. Advanced renal cell carcinoma. Curr. Treat. Options Oncol. 2, 437–445 (2001). (PMID: 1205710710.1007/s11864-001-0049-x)
Topalian, S. L. et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6, 839–853 (1988). (PMID: 325926110.1200/JCO.1988.6.5.839)
Rosenberg, S. A. et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889–897 (1987). (PMID: 349343210.1056/NEJM198704093161501)
Robertson, C. N. et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J. Urol. 144, 614–617 (1990). discussion 617-618. (PMID: 220179210.1016/S0022-5347(17)39537-X)
Walther, M. M., Yang, J. C., Pass, H. I., Linehan, W. M. & Rosenberg, S. A. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J. Urol. 158, 1675–1678 (1997). (PMID: 933457610.1016/S0022-5347(01)64091-6)
Bennett, R. T., Lerner, S. E., Taub, H. C., Dutcher, J. P. & Fleischmann, J. Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol. 154, 32–34 (1995). (PMID: 777644910.1016/S0022-5347(01)67217-3)
Flanigan, R. C. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071–1076 (2004). (PMID: 1476727310.1097/01.ju.0000110610.61545.ae)
Pantuck, A. J., Belldegrun, A. S. & Figlin, R. A. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N. Engl. J. Med. 345, 1711–1712 (2001). (PMID: 1175966010.1056/NEJM200112063452317)
Zini, L. et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 73, 342–346 (2009). (PMID: 1904112210.1016/j.urology.2008.09.022)
Rini, B. I. & Campbell, S. C. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J. Urol. 177, 1978–1984 (2007). (PMID: 1750927610.1016/j.juro.2007.01.136)
Abel, E. J. & Wood, C. G. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat. Rev. Urol. 6, 375–383 (2009). (PMID: 1952896010.1038/nrurol.2009.102)
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007). (PMID: 1721553010.1056/NEJMoa060655)
Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007). (PMID: 1815603110.1016/S0140-6736(07)61904-7)
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008). (PMID: 1865322810.1016/S0140-6736(08)61039-9)
Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007). (PMID: 1721552910.1056/NEJMoa065044)
Rini, B. I. et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422–5428 (2008). (PMID: 18936475265107410.1200/JCO.2008.16.9847)
Hudes, G. et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007). (PMID: 1753808610.1056/NEJMoa066838)
Choueiri, T. K. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185, 60–66 (2011). (PMID: 2107420110.1016/j.juro.2010.09.012)
Heng, D. Y. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur. Urol. 66, 704–710 (2014). (PMID: 2493162210.1016/j.eururo.2014.05.034)
Hanna, N. et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J. Clin. Oncol. 34, 3267–3275 (2016). (PMID: 27325852502454710.1200/JCO.2016.66.7931)
Petrelli, F. et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin. Genitourin. Cancer 14, 465–472 (2016). (PMID: 2713846110.1016/j.clgc.2016.04.001)
Garcia-Perdomo, H. A., Zapata-Copete, J. A. & Castillo-Cobaleda, D. F. Role of cytoreductive nephrectomy in the targeted therapy era: a systematic review and meta-analysis. Investig. Clin. Urol. 59, 2–9 (2018). (PMID: 2933350810.4111/icu.2018.59.1.2)
Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009). (PMID: 1982612910.1200/JCO.2008.21.4809)
Culp, S. H. et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116, 3378–3388 (2010). (PMID: 2056406110.1002/cncr.25046)
Mathieu, R. et al. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol. Oncol. 33, 339.e9-15 (2015). (PMID: 2608797110.1016/j.urolonc.2015.05.014)
Motzer, R. J. & Russo, P. Cytoreductive nephrectomy — patient selection is key. N. Engl. J. Med. 379, 481–482 (2018). (PMID: 2986090810.1056/NEJMe1806331)
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018). (PMID: 29562145597254910.1056/NEJMoa1712126)
Pierorazio, P. M. et al. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 100, 755–759 (2007). (PMID: 1782245610.1111/j.1464-410X.2007.07108.x)
Barbastefano, J. et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 106, 1266–1269 (2010). (PMID: 2034604210.1111/j.1464-410X.2010.09323.x)
Fallick, M. L., McDermott, D. F., LaRock, D., Long, J. P. & Atkins, M. B. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J. Urol. 158, 1691–1695 (1997). (PMID: 933458010.1016/S0022-5347(01)64097-7)
Bhindi, B. et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur. Urol. 75, 111–128 (2019). (PMID: 3046704210.1016/j.eururo.2018.09.016)
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015). (PMID: 26406148571948710.1056/NEJMoa1510665)
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019). (PMID: 3077952910.1056/NEJMoa1816714)
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019). (PMID: 30779531671660310.1056/NEJMoa1816047)
Dilme, R. V. et al. Cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: is there still a debate. Curr. Urol. Rep. 22, 54 (2021). (PMID: 3465498910.1007/s11934-021-01073-7)
Singla, N. et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol. Oncol. 38, 604.e9–604.e17 (2020). (PMID: 3225311610.1016/j.urolonc.2020.02.029)
Bakouny, Z. et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium. Eur. Urol. 83, 145–151 (2023). (PMID: 3627294310.1016/j.eururo.2022.10.004)
Aarhus University Hospital. US National Library of Medicine ClinicalTrials.gov NCT03977571 https://clinicaltrials.gov/ct2/show/NCT03977571 (2022).
National Cancer Institute. US National Library of Medicine ClinicalTrials.gov NCT04510597 https://clinicaltrials.gov/ct2/show/NCT04510597 (2022).
Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530–2540 (1999). (PMID: 1056131910.1200/JCO.1999.17.8.2530)
McIntosh, A. G. et al. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer 126, 3950–3960 (2020). (PMID: 3251584510.1002/cncr.32991)
Campbell, S. C., Flanigan, R. C. & Clark, J. I. Nephrectomy in metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 4, 363–372 (2003). (PMID: 1294119610.1007/s11864-003-0037-4)
Flanigan, R. C. Debulking nephrectomy in metastatic renal cancer. Clin. Cancer Res. 10, 6335S–6341S (2004). (PMID: 1544802710.1158/1078-0432.CCR-sup-040026)
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002). (PMID: 1177318110.1200/JCO.2002.20.1.289)
Leibovich, B. C. et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J. Urol. 174, 1759–1763 (2005). discussion 1763. (PMID: 1621727810.1097/01.ju.0000177487.64651.3a)
Zisman, A. et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649–1657 (2001). (PMID: 1125099310.1200/JCO.2001.19.6.1649)
Frank, I. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395–2400 (2002). (PMID: 1244192510.1016/S0022-5347(05)64153-5)
Yaycioglu, O. et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58, 141–145 (2001). (PMID: 1148968210.1016/S0090-4295(01)01207-9)
Karakiewicz, P. I. et al. Conditional survival predictions after nephrectomy for renal cell carcinoma. J. Urol. 182, 2607–2612 (2009). (PMID: 1983679810.1016/j.juro.2009.08.084)
Cindolo, L. et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 92, 901–905 (2003). (PMID: 1463284310.1111/j.1464-410X.2003.04505.x)
Margulis, V. et al. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur. Urol. 63, 947–952 (2013). (PMID: 2327368110.1016/j.eururo.2012.11.040)
Westerman, M. E. et al. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 126, 745–753 (2020). (PMID: 3262382110.1111/bju.15160)
Esdaille, A. R. & Abel, E. J. Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy. Cancer 127, 3920–3923 (2021). (PMID: 3428685510.1002/cncr.33788)
Wang, P., Chen, Y. & Wang, C. Beyond tumor mutation burden: tumor neoantigen burden as a biomarker for immunotherapy and other types of therapy. Front. Oncol. 11, 672677 (2021). (PMID: 33996601811723810.3389/fonc.2021.672677)
Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017). (PMID: 29262275654968810.1056/NEJMc1713444)
Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655–1661 (2018). (PMID: 3029791110.1038/s41591-018-0198-0)
MacFarlane, A. W. et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol. Res. 2, 320–331 (2014). (PMID: 2476457910.1158/2326-6066.CIR-13-0133)
Abel, E. J. et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur. Urol. 59, 10–15 (2011). (PMID: 2095212310.1016/j.eururo.2010.09.034)
Panian, J. et al. Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 40, 334–334 (2022). (PMID: 10.1200/JCO.2022.40.6_suppl.334)
Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829–841 (2021). (PMID: 33657295843659110.1056/NEJMoa2026982)
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 20, 1370–1385 (2019). (PMID: 31427204749787010.1016/S1470-2045(19)30413-9)
Meerveld-Eggink, A. et al. Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: real-world data assessment. Eur. Urol. Open. Sci. 35, 54–58 (2022). (PMID: 35024632873889910.1016/j.euros.2021.11.003)
Albiges, L. et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): final analysis from the NIVOREN GETUG AFU 26 study. J. Clin. Oncol. 37, 542–542 (2019). (PMID: 10.1200/JCO.2019.37.7_suppl.542)
Courcier, J. et al. Primary renal tumour response in patients treated with nivolumab for metastatic renal cell carcinoma: results from the GETUG-AFU 26 NIVOREN trial. Eur. Urol. 80, 325–329 (2021). (PMID: 3410318110.1016/j.eururo.2021.05.020)
Carlo, M. I. et al. Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy. Eur. Urol. 81, 570–573 (2022). (PMID: 35183395915654110.1016/j.eururo.2022.01.043)
Gorin, M. A. et al. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur. Urol. Oncol. 5, 113–117 (2022). (PMID: 3404984710.1016/j.euo.2021.04.002)
Abel, E. J. et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur. Urol. 60, 1273–1279 (2011). (PMID: 21784574437871410.1016/j.eururo.2011.07.008)
Powles, T. et al. Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer. JAMA Oncol. 2, 1303–1309 (2016). (PMID: 2725475010.1001/jamaoncol.2016.1197)
Mejean, A. et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy. Eur. Urol. 80, 417–424 (2021). (PMID: 3418777110.1016/j.eururo.2021.06.009)
Bhindi, B. et al. Comparative survival following initial cytoreductive nephrectomy versus initial targeted therapy for metastatic renal cell carcinoma. J. Urol. 200, 528–534 (2018). (PMID: 2957410910.1016/j.juro.2018.03.077)
Macleod, L. C. et al. Comparative effectiveness of initial surgery vs initial systemic therapy for metastatic kidney cancer in the targeted therapy era: analysis of a population-based cohort. Urology 113, 146–152 (2018). (PMID: 2917494210.1016/j.urology.2017.11.014)
Abel, E. J. et al. Multi-quadrant biopsy technique improves diagnostic ability in large heterogeneous renal masses. J. Urol. 194, 886–891 (2015). (PMID: 2583753510.1016/j.juro.2015.03.106)
Woldu, S. L. et al. Incidence and outcomes of delayed targeted therapy after cytoreductive nephrectomy for metastatic renal-cell carcinoma: a nationwide cancer registry study. Clin. Genitourin. Cancer 16, e1221–e1235 (2018). (PMID: 3021776310.1016/j.clgc.2018.08.001)
Roussel, E. et al. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. Scand. J. Urol. 54, 493–499 (2020). (PMID: 3292472910.1080/21681805.2020.1814858)
Rini, B. I. et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 17, 1317–1324 (2016). (PMID: 27498080919945310.1016/S1470-2045(16)30196-6)
Zhang, Y. et al. Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int. J. Radiat. Oncol. Biol. Phys. 105, 367–375 (2019). (PMID: 31377159764738110.1016/j.ijrobp.2019.07.023)
Tang, C. et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 22, 1732–1739 (2021). (PMID: 3471779710.1016/S1470-2045(21)00528-3)
Hannan, R. et al. Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2021.12.001 (2021). (PMID: 10.1016/j.euo.2021.12.001)
de Velasco, G. et al. Comprehensive analysis of survival outcomes in non-clear cell renal cell carcinoma patients treated in clinical trials. Clin. Genitourin. Cancer 15, 652–660.e651 (2017). (PMID: 2841091110.1016/j.clgc.2017.03.004)
Pal, S. K. et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 397, 695–703 (2021). (PMID: 33592176868773610.1016/S0140-6736(21)00152-5)
Armstrong, A. J. et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 17, 378–388 (2016). (PMID: 26794930686315110.1016/S1470-2045(15)00515-X)
Tannir, N. M. et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur. Urol. 69, 866–874 (2016). (PMID: 2662661710.1016/j.eururo.2015.10.049)
Kroeger, N. et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 119, 2999–3006 (2013). (PMID: 2369612910.1002/cncr.28151)
Motzer, R. J. et al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 20, 71–90 (2022). (PMID: 10.6004/jnccn.2022.0001)
Graham, J. et al. Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur. Urol. Oncol. 2, 643–648 (2019). (PMID: 31411994688623810.1016/j.euo.2019.03.007)
Aizer, A. A. et al. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 113, E67–E74 (2014). (PMID: 24053727411770210.1111/bju.12442)
Alnimer, Y., Qasrawi, A., Yan, D. & Wang, P. Prognostic impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: data from a large population-based database. Urol. J. 19, 111–119 (2021). (PMID: 34739723)
Marchioni, M. et al. Survival after cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients: a population-based study. Eur. Urol. Focus. 5, 488–496 (2019). (PMID: 2922958210.1016/j.euf.2017.11.012)
Luzzago, S. et al. Association between systemic therapy and/or cytoreductive nephrectomy and survival in contemporary metastatic non-clear cell renal cell carcinoma patients. Eur. Urol. Focus. 7, 598–607 (2021). (PMID: 3244430310.1016/j.euf.2020.04.009)
Minnillo, B. J. et al. Cytoreductive nephrectomy in the modern era: predictors of use, morbidity, and survival. Can. Urol. Assoc. J. 11, E184–E191 (2017). (PMID: 28503232542693910.5489/cuaj.4137)
Pignot, G. et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur. Urol. 77, 761–763 (2020). (PMID: 3191101110.1016/j.eururo.2019.12.018)
Singla, N. et al. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urol. Oncol. 37, 924–931 (2019). (PMID: 31522865948922910.1016/j.urolonc.2019.08.012)
Tennenbaum, D. M. et al. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urol. Oncol. 35, 532.e537–532.e513 (2017). (PMID: 10.1016/j.urolonc.2017.03.015)
Ged, Y. & Voss, M. H. Novel emerging biomarkers to immunotherapy in kidney cancer. Ther. Adv. Med. Oncol. 13, 17588359211059367 (2021). (PMID: 34868351864028410.1177/17588359211059367)
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015). (PMID: 26359337505451710.1126/science.aad0095)
Ricciuti, B. et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 8, 1160–1168 (2022). (PMID: 35708671920462010.1001/jamaoncol.2022.1981)
McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018). (PMID: 29867230672189610.1038/s41591-018-0053-3)
Labriola, M. K. et al. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. J. Immunother. Cancer https://doi.org/10.1136/jitc-2019-000319 (2020). (PMID: 10.1136/jitc-2019-000319322210167206964)
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med. 26, 1733–1741 (2020). (PMID: 32895571849348610.1038/s41591-020-1044-8)
Motzer, R. J. et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 38, 803–817.e4 (2020). (PMID: 33157048843659010.1016/j.ccell.2020.10.011)
Wu, Q., Huang, G., Wei, W. & Liu, J. Molecular imaging of renal cell carcinoma in precision medicine. Mol. Pharm. https://doi.org/10.1021/acs.molpharmaceut.2c00034 (2022). (PMID: 10.1021/acs.molpharmaceut.2c00034365717959644396)
Bootsma, M. et al. Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma. J. Clin. Oncol. 40, 3633–3641 (2022). (PMID: 3561764610.1200/JCO.22.00219)
Li, Y., Chen, P. & Chen, Z. Diagnostic value of circulating cell-free DNA for renal cell carcinoma: a meta-analysis. Transl. Cancer Res. 10, 2265–2276 (2021). (PMID: 35116544879901110.21037/tcr-20-3448)
Marchioni, M. et al. Development of a novel risk score to select the optimal candidate for cytoreductive nephrectomy among patients with metastatic renal cell carcinoma. results from a multi-institutional registry (REMARCC). Eur. Urol. Oncol. 4, 256–263 (2021). (PMID: 3338427410.1016/j.euo.2020.12.010)
Klatte, T. et al. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. World J. Urol. 36, 417–425 (2018). (PMID: 2925602010.1007/s00345-017-2154-x)
Patel, M. I., Beattie, K., Bang, A., Gurney, H. & Smith, D. P. Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival. Cancer Med. 6, 2188–2193 (2017). (PMID: 28834281563359110.1002/cam4.1137)
Day, D. et al. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma. Intern. Med. J. 46, 1291–1297 (2016). (PMID: 2750762910.1111/imj.13202)
de Groot, S. et al. Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: results from a population-based registry. Urology 95, 121–127 (2016). (PMID: 2717977310.1016/j.urology.2016.04.042)
Conti, S. L. et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int. J. Cancer 134, 2245–2252 (2014).
You, D. et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J. Urol. 185, 54–59 (2011). (PMID: 2107481110.1016/j.juro.2010.09.018)
المشرفين على المادة: 0 (Immune Checkpoint Inhibitors)
0 (Interferon-alpha)
تواريخ الأحداث: Date Created: 20230703 Date Completed: 20231103 Latest Revision: 20240129
رمز التحديث: 20240129
DOI: 10.1038/s41585-023-00776-5
PMID: 37400492
قاعدة البيانات: MEDLINE
الوصف
تدمد:1759-4820
DOI:10.1038/s41585-023-00776-5